Edwards Lifesciences Corporation
EW
Rank in Stocks
#484
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Share Price
$87.29
Last synced: 2026-10-19
Market Cap
$50.31B
Change (1 day)
0.96%
Change (1 year)
15.94%
Country
US
Trade Edwards Lifesciences Corporation (EW)
Category
Healthcare
Revenue for Edwards Lifesciences Corporation (EW)
Revenue in Jun 2026 TTM: $6.51B
According to Edwards Lifesciences Corporation latest financial reports the company's current revenue (TTM) is $6.51B. In 2024 the company made a revenue of $5.44B an increase over the revenue in the year 2023 that was $5.01B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Edwards Lifesciences Corporation from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $6.51B | 7.33% |
| 2025 | $6.07B | 11.55% |
| 2024 | $5.44B | 8.57% |
| 2023 | $5.01B | -6.92% |
| 2022 | $5.38B | 2.86% |
| 2021 | $5.23B | 19.29% |
| 2020 | $4.39B | 0.88% |
| 2019 | $4.35B | 16.79% |
| 2018 | $3.72B | 8.37% |
| 2017 | $3.44B | 15.91% |
| 2016 | $2.96B | 18.85% |
| 2015 | $2.49B | 7.35% |
| 2014 | $2.32B | 13.56% |
| 2013 | $2.05B | 7.68% |
| 2012 | $1.90B | 13.17% |
| 2011 | $1.68B | 16.01% |
| 2010 | $1.45B | 9.51% |
| 2009 | $1.32B | 6.76% |
| 2008 | $1.24B | 13.44% |
| 2007 | $1.09B | 5.22% |
| 2006 | $1.04B | 3.92% |
| 2005 | $997.90M | 7.13% |
| 2004 | $931.50M | 8.25% |
| 2003 | $860.50M | 22.23% |
| 2002 | $704.00M | 1.73% |
| 2001 | $692.00M | -13.93% |
| 2000 | $804.00M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $46.59B | 615.34% |
US
|
|
| $35.48B | 444.88% |
IE
|
|
| $25.84B | 296.74% |
US
|
|
| $21.00B | 222.41% |
US
|
|
| - | - |
DE
|
